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A Proposal for a Classification for Recurrent
Endometrial Cancer
Analysis of a French Multicenter Database From the
FRANCOGYN Study Group
Alexandre Bricou, MD,* Sofiane Bendifallah, MD, PhD,Þ Mathilde Daix-Moreux, MD,*
Lobna Ouldamer, MD, PhD,þ Vincent Lavoue, MD, PhD,§ Amélie Benbara, MD,*
Cyrille Huchon, MD, PhD,|| Geoffroy Canlorbe, MD, PhD,Þ Emilie Raimond, MD,¶
Charles Coutant, MD, PhD,# Olivier Graesslin, MD, PhD,¶ Pierre Collinet, MD, PhD,**
Xavier Carcopino, MD, PhD,ÞÞ Cyril Touboul, MD, PhD,þþ§§ Emile DaraB, MD, PhD,Þ
Lionel Carbillon, MD, PhD,* and Marcos Ballester, MD, PhD,Þ
for the Groupe de Recherche FRANCOGYN
Objective: Endometrial cancer (EC) recurrences are relatively commonwith no standardized
way of describing them. We propose a new classification for them called locoregional, nodal,
metastasis, carcinomatosis recurrences (rLMNC).
Patients and Methods: The data of 1230 women with EC who were initially treated by
primary surgery were included in this French multicenter retrospective study. Recurrences
were classified based on dissemination pathways: (1) locoregional recurrence (rL); (2) nodal
recurrence (rN) for lymphatic pathway; (3) distant organ recurrence (rM) for hematogenous
pathway; and (4) carcinomatosis recurrence (rC) for peritoneal pathway. These pathways
were further divided into subgroups. We compared recurrence free survival and overall
survival (OS) between the 4 groups (rL/rN/rM/rC).
Results: The median follow-up was 35.6 months (range, 1.70Y167.60). One hundred
ninety-eight women (18.2%) experienced a recurrence: 150 (75.8%) experienced a single-
pathway recurrence and 48 (24.2%) amultiple-pathway recurrence. The 5-year OSwas 34.1%
(95% confidence interval [CI], 27.02%Y43.1%), and the median time to first recurrence was
18.9 months (range, 0Y152 months). The median survival after recurrence was 14.8 months
(95%CI, 11.7Y18.8). Amongwomenwith single pathway of recurrence, a difference in 5-year
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OS (PG 0.001) and survival after recurrence (PG 0.01)was foundbetween the 4 rLNMCgroups.
The carcinomatosis group had the worst prognosis compared with other single recurrence
pathways.Womenwithmultiple recurrences had poorer 5-year OS (PG 0.001) and survival after
recurrence (P G 0.01) than those with single metastasis recurrence, other than women with
peritoneal carcinomatosis.
Conclusions: This easy-to-use and intuitive classification may be helpful to define EC
recurrence risk groups and develop guidelines for the management of recurrence. Its
prognosis value could also be a tool to select homogenous populations for further trials.
Key Words: Endometrial cancer, Recurrences, Relapses, Classification
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Endometrial cancer (EC) is the most common gynecologiccancer worldwide with 320,000 new cases each year.1
Around 75% of ECs are diagnosed at an early stage with a
5-year overall survival (OS) reaching 80%.2 However, EC is a
heterogeneous disease with some subsets of women displaying
an increased risk of recurrence. Indeed, it causes almost 76,000
deaths per year.1 The most usual identified risk factors for re-
currence are the International Federation of Gynecology and
Obstetrics (FIGO) stage, depth of myometrial invasion, histolog-
ical type and grade, lymphovascular space invasion, and tumor
size.3 In this specific setting, the European Society for Medical
Oncology (ESMO)/European Society of Gynaecological
Oncology/European Society for Radiotherapy and Oncology
group recently classified ECwomen into 4 subgroups according
to the risk of recurrence (low risk, intermediate risk, high-
intermediate risk, and high risk) to better adapt surgical staging
and indications for adjuvant therapies.4
Although overall prognosis of women with surgically
treated EC is good, Bendifallah et al5 recently reported that at
least 20% of them will experience a recurrence, impacting OS.
Moreover, it is now well recognized that more than 70% of
recurrences occur within the first 2 to 3 years after initial
treatment.6Y8 Hence, recurrence events and their treatment are a
crucial aspect in themanagement ofwomenwithEC.Most studies
to date focus on predictive factors of recurrence, recurrence pat-
terns, and specific treatments.9Y11 In this setting, most authors
concur that locoregional recurrences are to be differentiated
from distant recurrences.
However, there is currently no consensual standardized
description of EC recurrence and definitions vary widely from
one study to another.12Y16 This lack of homogeneity limits
comparison of study results by rendering their interpretation
somewhat blurred.
Hence, the purpose of this study was to describe the
anatomical locations of EC recurrence with a view to devel-
oping an easy-to-use classification basedon the 4dissemination
pathways (locoregional, lymphatic, blood, and peritoneal) to
better assess prognosis.
PATIENTS AND METHODS
Study Population
From January 2001 to December 2013, data of women
with histologically proven EC who received primary surgical
treatment were abstracted from EC databases of 9 institutions
in France (Tours University Hospital, Tenon University
Hospital, Dijon Cancer Centre, Rennes University Hospital,
Lille University Hospital, Reims University Hospital, Creteil
University Hospital, Poissy University Hospital, and Jean
Verdier University Hospital) and from the Senti-Endo trial.17
The research protocol was approved by the Institutional
Review Board of the Collège National des Gynécologues et
Obstétriciens Français (CEROG 2014-GYN-020).
All enrolled women underwent preoperative imaging
examinations (abdominopelvic magnetic resonance imaging
and/or computed tomography scan). The following clinical,
surgical, pathological, and adjuvant therapydatawere collected:
women’s age, body mass index (BMI; calculated as weight in
kilograms divided by the square of height in meters), surgical
procedure, nodal staging, final pathological analysis (histologi-
cal type and grade, depth of myometrial invasion, and
lymphovascular space invasion status), and type of adjuvant
therapy. Histological type 1 included endometrioid tumors
(grades 1 to 3), and histological type 2 included serous or clear-
cell carcinomas and carcinosarcomas. All women were clas-
sified according to the FIGO 2009 classification18 after final
pathological analysis and were classified into recurrence risk
groups as defined by the ESMO/European Society of
Gynaecological Oncology/European Society for Radiother-
apy and Oncology guidelines.4
Treatment and Follow-up
All the women underwent primary surgical treatment
including at least total hysterectomy with bilateral salpingo-oo-
phorectomy, with or without nodal staging (sentinel lymph nodes
T pelvic T para-aortic lymphadenectomy), aswell as omentectomy.
Adjuvant therapy and clinical follow-up were decided by a
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multidisciplinary committee and based on the French guidelines.
Adjuvant therapy could include vaginal brachytherapy and/or ex-
ternal beam radiotherapy (EBRT) and/or chemotherapy (CT).
Clinical follow-up consisted of physical examinations and the use
of imaging techniques according to the findings. Follow-up visits
were conducted every3months for the first 2 years, every6months
for the following 3 years, and once a year thereafter.
Recurrence Events and Classification
Recurrent disease was assessed by physical examination
and imaging techniques (computed tomography, magnetic res-
onance imaging, ultrasonography, bone scintigraphy, positron
emission tomography with the fluorodesoxyglucose (18F) as
well as histological findings when feasible. We applied a new
classification, called the rLNMC classification, based on the
pathway of dissemination: locoregional recurrence (rL), nodal
recurrence (rN), distant organ recurrence (rM), and peritoneal
recurrence with carcinomatosis (rC) (Table 1). Locoregional
pathway recurrence was divided into 2 groups as follows: re-
currence in the vaginal vault only (rL1) and rectal and/or
bladder involvement (rL2). We defined a locoregional recur-
rence that could not be assessed (rLx) and no evidence of
locoregional recurrence as rL0. Nodal recurrences were sepa-
rated into 2 groups: for lymph node recurrence in the pelvic,
inguinal, and/or infradiaphragmatic para-aortic area (rN1) and
for mediastinal or other distance nodal recurrences (rN2). We
defined a node recurrence that could not be assessed as rNx and
no evidence of the recurrent node site as rN0. Hematogenous
recurrences were also divided into 2 groups: single metastasis
(rM1) and multiple metastasis (rM2). We defined a metastatic
recurrence that could not be assessed as (rMx) and no evidence
of the metastatic as (rM0). The peritoneal recurrence rep-
resented a single group for pelvic and/or abdominal carci-
nomatosis (rC1). We defined a peritoneal recurrence that
could not be assessed as rCx and no evidence of carcino-
matosis as (rC0). Single recurrence was defined as recur-
rence with only one pathway of dissemination. Multiple
recurrences were defined as recurrences with more than one
pathway of dissemination, Supplemental Digital Content 1,
http://links.lww.com/IGC/A754;Supplemental Digital Content 2,
http://links.lww.com/IGC/A755.
Statistical Analysis
Recurrence free survival was defined as the length of
time from the date of primary surgery to any EC recurrence
and was censored at the date of the last follow-up or date of
death without recurrence. Overall survival was defined as time
from primary surgery to death as a result of any cause and survival
after recurrencewas defined as time from recurrence diagnostic to
death. Kaplan-Meier estimates were used to estimate the event-
time distributions, and log-rank test was used to compare the
differences in terms of OS between the 4 groups (rL/rN/rM/rC).
Values of P G 0.05 were considered to denote significant
differences. Data were managed with an Excel database
(Microsoft, Redmond, Wash) and analyzed using R 2.15 soft-
ware, available onlinewith caTools, rms, presence/absence, and
verification libraries (https://www.r-project.org/).
RESULTS
Characteristics of the Population
During the study period, 1230 women with EC who
were initially treated by primary surgery were included in this
multicenter retrospective study. Two hundred twenty-four women
(18.2%) experienced a recurrence. Among them, 26 were ex-
cluded owing to incomplete data leaving 198 women for final
analysis. The median age of the women with recurrence was
68.5years (range, 32Y88years), and theirBMIwas29.09 kg/m2
(range, 14Y50.4 kg/m2). The median follow-up was 35.6
months (range, 1.70Y167.60 months) after primary diagnosis
and 10.2 months (range, 1Y109 months) after recurrence. The
median recurrence free survivalwas 18.9months (range, 0Y152
months). The 5-year OSwas 34.1% (95%CI, 27.02%Y43.1%).
Themedian survival after recurrencewas 14.8months (95%CI,
11.7Y18.8). One hundred nineteen women (60%) died, and
65 (55%) of these deaths were due to EC recurrence. For the
remaining 54 women, the cause of the death was not recorded.
The characteristics of the women with recurrence are reported
in Table 2.
TABLE 1. rLMNC classification for EC recurrence
rLocoregional
rLx A recurrence tumor that cannot be assessed
rL0 No evidence of the recurrent tumor site
rL1 Recurrence tumor in the vaginal vault only
rL2 Centropelvic recurrence tumor with or
without rectal and/or bladder
involvement.
rNode
rNx The lymph node recurrence cannot
be assessed
rN0 No lymph node recurrence
rN1 Lymphnode recurrence in pelvic, inguinal,
and/or infradiaphragmatic para-aortic area
rN2 Mediastinal or other distance lymph
node recurrence
rMetastasis
rMx Distant organ recurrence cannot be assessed
rM0 No distant organ recurrence
rM1 Distant recurrence in one organ
rM2 Distant recurrence in two or more organs.
rCarcinomatosis
rCx Carcinomatosis recurrence cannot be assessed
rC0 No carcinomatosis recurrence
rC1 Presence of carcinomatosis recurrence
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Patterns of Recurrence According to the
rLNMC Classification
Among the 198 women who experienced recurrence:
52 (21.1%) experienced a locoregional recurrence (vaginal
vault [rL1] in 22 cases [8.9%], centropelvic recurrence [rL2] in
30 cases [12.2%]); 50 (20.3%) experienced a nodal recurrence
(pelvic, inguinal, and/or para-aortic node recurrence [rN1] in 41
cases [16.7%] and mediastinal or distant nodes [rN2] in 9 cases
[3.8%]); 95 (38.6%) experienced a metastatic pathway recur-
rence (rM1) in 49 cases (19.9%) and rM2 in 46 cases (18.7%);
and 49 (19.9%) experienced a peritoneal carcinomatosis re-
currence (rC1).
Among the women who experienced a single recur-
rence (n = 150, 75.8%): 30 (20%) experienced a tumor site
recurrence (vaginal recurrence [rL1N0M0C0] in 14 cases
[46.7%], centropelvic recurrence [rL2N0M0C0] in 16 cases
[53.3%]); 26 (17.3%) experienced a nodal recurrence (pelvic,
para-aortic, or inguinal areas [rL0N1M0C0] in 18 cases
[69.2%] and mediastinal or distance nodes [rL0N2M0C0] in
8 cases [30.8%]); and 65 (43.3%) experienced a metastatic
recurrence (only 1 localization [rL0N0M1C0] in 32 cases
[49.2%] [15 lung, 8 bone, 6 brain, 2 liver, 1 unspecified], more
than 1 [rL0N0M2C0] in 33 cases [50.8%], and peritoneal
carcinomatosis recurrence (rL0N0M0C1) in 29 cases [19.4%]).
Among the women who experienced a multiple recur-
rence (n = 48 [24.2%]): 22 (45.8%) experienced a locoregional
recurrence (vaginal vault [rL1] in 8 cases [36.4%], centropelvic
[rL2] in 14 cases [63.6%]); 24 (50%) experienced a nodal re-
currence (involving pelvic, para-aortic, or inguinal area nodes
[rN1] in 23 cases [95.8%] and mediastinal area or distance
nodes [rN2] in 1 case [4.2%]); and 30 (62.5%) experienced a
metastatic recurrence (1metastasis [8 lung, 7 liver, 1 unspecified,
1 bone] [rM1] in 17 cases [56.7%], more than 1 metastatic re-
currence [rM2] in 13 cases [43.3%] [Table 3], and peritoneal
carcinomatosis [rC1] in 20 cases [41.7%]).
Survival Outcomes
The 5-year OS was 34.1% (95% CI, 27,02Y43,1%)
(Fig. 1A). Themedian survival after recurrencewas 14.8months
(95% CI, 11.7Y18.8) (Fig. 1B). Among women with single
pathway of recurrence, a difference in 5-year OS (Fig. 2A)
and survival after recurrence (Fig. 2B)was found between the
4 rLNMC groups. The carcinomatosis group (rL0N0M0C1)
had the worst prognosis compared with other single recurrence
pathways.Whenconsideringwomenwithmultiple recurrences,
a difference in 5-yearOS (Fig. 3A) and survival after recurrence
(Fig. 3B) was found between the rLNMC groups.
DISCUSSION
Our study confirms that the patterns of recurrence in EC
are multiple. Moreover, it shows that recurrence sites can be
isolated or associated with each other: we identified 246
different recurrences among the 198 women who experienced
recurrence with 75.8% experiencing single recurrence and
(24.2%) multiple recurrences. These results are in agreement
with those of Sohaib et al12 who report 48% of multiple-site
recurrences. This is why the rLNMC classification we propose
here includes the different pathways of spread: locoregional
TABLE 2. Characteristics of women who experienced
a recurrence
Characteristics Population, n = 198
Age, median (range), y 68.49 (32Y88)
BMI, median (range), kg/m2 29.09 (14Y50.4)
Follow-up, median (range), mo 35.6 (1.70Y167.60)
Histological type n (%)
Type 1 115 (58)
Type 2 83 (42)
ESMO classification n (%)
Low risk 18 (9.1)
Intermediate risk 9 (4.5)
Intermediate-high risk 18 (9.1)
High risk 151 (76.3)
NA 2 (1)
FIGO stage at definitive histology n (%)
I 86 (43.4)
II 26 (13.1)
III 73 (36.9)
IV 13 (6.6) (13)
Adjuvant therapies before recurrence n (%)
No adjuvant therapy 30 (15.2)
Vaginal brachytherapy alone 13 (6.6)
EBRT + brachytherapy 64 (32.3)
CT + EBRT 21 (10.6)
CT alone 28 (14.1)
EBRT + brachytherapy + CT 27 (13.6)
EBRT alone 14 (7.1)
Brachytherapy + CT 1 (0.5)
NA, not available.
TABLE 3. Women with single or multipathways of
recurrence with rLNMC classification
Single recurrence on locoregional site (rL) 30 (15.2%)
rL1N0M0C0 14
rL2N0M0C0 16
Single-nodes recurrence (rN) 26 (13.2%)
rL0N1M0C0 18
rL0N2M0C0 8
Single-metastasis recurrence (rM) 65 (32.8%)
rL0N0M1C0 32
rL0N0M2C0 33
Single-carcinomatosis recurrence (Rc) 29 (14.6%)
rL0N0M0C1 29
Multiple-pathways recurrence (rMpath) 48 (24.2%)
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extension (contiguous extension), lymphatic dissemination
(nodal recurrences), hematogenous dissemination (metastatic
recurrences), and peritoneal seeding (carcinomatosis). It is
based on clinical and/or imaging data foundduring the follow-up
period with or without histological confirmation and describes
localization, type, and focality of recurrences. Moreover, local-
ization of recurrence is not the only prognostic factor; prognosis
may also depend on the type of recurrence treatment, which is
conditioned by (1) initial treatment (radiotherapy), (2) the
interval between initial diagnosis and recurrence, and (3) the
initial histology and tumor grade.13 Hence, our classification
could be completed by the type of early adjuvant treatment
used. Consequently, the prefixes Ra for radiotherapy, Ch
for CT, and Ht for hormonotherapy could also be recorded
in the classification.
In the classification we present here, locoregional re-
currence (rL) concerns recurrences localized in the locoregional
area and related to contiguous dissemination (from the initial
EC tumor site). In this specific setting, we decided to exclude
parenchimatous recurrences from this group and include them
in the hematogenous pathway (metastasis) group, even if such
recurrences can involve abdominal or pelvic organs.Our division
into 2different subgroups (rL1, rL2) is supportedby its impact on
OS: a trend for poorer prognosis was found for centropelvic
recurrences (rL2, N0, M0, C0) compared with vaginal vault
recurrences (rL1, N0, M0, C0). Therapeutic options are an
additional parameter supporting this distribution. Indeed, sur-
gical treatment can be more difficult and sometimes not pos-
sible for centropelvic recurrences as opposed to isolated vaginal
vault recurrence, which can often be salvaged with surgical
excision and/or radiotherapy. In this setting, Ackerman et al19
reported a local control rate of up to 79% for isolated vaginal
vault recurrences.Moreover, several studies report that survival
is better in women with recurrence confined within the vaginal
vault rather than in the true pelvis13,20Y22 or other sites.23 How-
ever, these results must be interpreted with caution because the
prognosis seems to be the poorest for women who initially re-
ceived external beam radiotherapy.13 Concerning centropelvic
recurrences (rL2), the extent of recurrence appears to be an
important prognostic factor for local control and survival.24 In a
series of 209womenwith recurrence, Sartori et al23 reported that
the 5-year OS for vaginal, pelvic, and distant recurrence was
68%, 29%, and 8%, respectively.
Concerning the lymphatic pathway, nodal recurrences
represented 20.3% of the total recurrence sites in our study
and were isolated in 13.1% of cases. These findings are in
contradiction with those of Sohaib et al12 who found that
nodal recurrenceswere themost frequent recurrence site (47%).
FIGURE 1. A, Five-year cumulative survival rates for the whole population. B, Cumulative survival rates after
recurrence for the whole population.
FIGURE 2. A, Five-year cumulative survival rates for the different single recurrences. B, Cumulative survival rates after
recurrence for different single recurrences.
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However, their study included 86patients amongwhomonly 40
(46.5%) had undergone nodal dissection during primary sur-
gery.12 We distinguish between 2 types nodal recurrence in
our classification: rN1 for all pelvic, inguinal, and/or
infradiaphragmatic para-aortic area node recurrence and rN2
for mediastinal or other distant lymph node recurrence. This
distinction is based on the possibility of surgical removal for
the rN1 group compared with the rN2 group. However, we
were not able to distinguish pelvic node involvement from
infradiaphragmatic para-aortic or inguinal nodal involvement
in the database. Moreover, we did not find any difference in
survival between the rN1 and the rN2 groups, when isolated.
This can be explained by the fact that isolated rN2 recurrences
are rare and that nodal recurrences are often associated with
other recurrence sites. However, a few studies in the literature
have attempted to distinguish between type of nodal involve-
ment and what we consider to be the rN2 group is often clas-
sified as distant recurrence sites.5,21,22,25
In our study, metastases represented the first pathway of
recurrence and was found in 95 women (38.6%) with a similar
distribution between isolated and multiple metastases. This
rate is in complete agreement with that reported by Sohaid
et al12 who found thatmetastasesoccurred in36%of recurrences
and represented a major predictor factor for poor survival. In
the current classification, we decided to classify metastatic
recurrences as single (rM1) or multiple (rM2). We believe that
single metastases could be, in selected cases, eligible for local
control (surgery or interventional imaging) with a view to in-
creasing the symptom-free interval, which is less feasible for
multiple-site metastases. In contrast, we decided not to distin-
guish between the different anatomical sites because this would
detract from the clarity and ease-of-use of the classification.
In our study, the presence of peritoneal carcinomatosis
was linked to a significant decrease in 5-years OS and survival
after recurrence. That iswhywe decided to create a single group
because itmay represent a specific pathwayof dissemination. In
the current literature, the real impact of peritoneal carcinoma-
tosis on survival remains unclear because it is often associ-
ated with other recurrence sites such as distant metastases,
extravaginal recurrences, or abdominal recurrences.22,26Y28
Indeed, Ouldamer et al29 recently reported a nomogram to
predict poor prognosis recurrences (ie, peritoneal carcinomatosis
and distant metastases) with a 3-year OS of 33.1% for the
peritoneal carcinomatosis group. Finally, the treatment options
maydiffer dependingonwhether the peritoneal carcinomatosis is
isolated or associated to another pathway of dissemination. In
this setting, in case of isolated carcinomatosis, the place of
cytoreductive surgery with hyperthermic intraperitonal CT is a
matter of major interest.
The strengths of our study lie in its multicenter nature
and the large number of women with EC recurrence included.
However, we cannot exclude an inherent bias linked to its
retrospective nature. Indeed, among the 224 women who ex-
perienced a recurrence, 26 (11.6%) were excluded owing to
incomplete data. Moreover, our database did not allow to dif-
ferentiate pelvic nodes involvement, infradiaphragmatic para-
aortic area nodes involvement, and inguinal nodes involvement.
Finally, during the data collection period, modifications oc-
curred in surgical techniques such as lymph node staging and
indications for adjuvant therapies with potential impact on
prognosis. However, all women were managed in regional re-
ferral centers with a systematic multidisciplinary committee
approval in accordance with French/Europeans guidelines.30
In conclusion, EC recurrences represent a heterogeneous
group ofwomenwith various histological characteristics, initial
treatments, and anatomical sites of recurrence. Such hetero-
geneity has beenwidely described, but, to our knowledge, this is
the first study to propose a classification including standardized
definitions of recurrence based on the different pathways of
dissemination. A consensual classification would not only
make it easier to better define risk groups and develop guide-
lines for the surgical or medical management of EC recurrence
but also help select homogenous populations for further trials.
This first classification for EC recurrence should, naturally, be
further developed and updated.
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